Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Idraparinux. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Idraparinux. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Idraparinux. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Idraparinux is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Idraparinux. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Idraparinux. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Idraparinux is combined with Obinutuzumab. |
| Rivaroxaban | Idraparinux may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Idraparinux is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Idraparinux. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Idraparinux. |
| Urokinase | Urokinase may increase the anticoagulant activities of Idraparinux. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Idraparinux. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Idraparinux. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Idraparinux. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Idraparinux. |
| Quinine | The therapeutic efficacy of Idraparinux can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Idraparinux can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Idraparinux. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Idraparinux. |
| Pentoxifylline | The therapeutic efficacy of Idraparinux can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Idraparinux. |
| Levocarnitine | The therapeutic efficacy of Idraparinux can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Idraparinux. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Idraparinux. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Idraparinux. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Idraparinux. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Idraparinux. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Idraparinux. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Idraparinux. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Idraparinux. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Idraparinux. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Idraparinux. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Idraparinux. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Idraparinux. |
| Equol | Equol may decrease the anticoagulant activities of Idraparinux. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Idraparinux. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Idraparinux. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Idraparinux. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Idraparinux. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Idraparinux. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Idraparinux. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Idraparinux. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Idraparinux. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Idraparinux. |
| Estriol | Estriol may decrease the anticoagulant activities of Idraparinux. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Idraparinux. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Idraparinux. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Idraparinux. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Idraparinux. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Idraparinux. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Idraparinux. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Idraparinux. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Idraparinux. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Idraparinux. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Idraparinux. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Idraparinux. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Idraparinux. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Idraparinux. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Idraparinux. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Idraparinux. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Idraparinux. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Idraparinux. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Idraparinux. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Idraparinux. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Idraparinux. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Idraparinux. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Idraparinux. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Idraparinux. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Idraparinux. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Idraparinux. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Idraparinux. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Idraparinux. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Idraparinux. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Idraparinux. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Idraparinux. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Idraparinux. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Idraparinux. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Idraparinux. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Idraparinux. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Idraparinux. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Idraparinux. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Idraparinux. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Idraparinux. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Idraparinux. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Idraparinux. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Idraparinux. |